Research Topics
| Amanda F CashenSummaryAffiliation: Washington University School of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Salvage regimens for Hodgkin lymphomaAmanda F Cashen
Washington University School of Medicine, St Louis, MO 63110, USA
Clin Adv Hematol Oncol 6:517-24. 2008....- Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabineAmanda F Cashen
Department of Medicine, Division of Bone Marrow Transplantation and Stem Cell Biology, Washington University School of Medicine, St Louis, Missouri, USA
Am J Hematol 81:543-5. 2006..He was retreated with decitabine and again achieved a CR, which has been maintained for 6 months. This case demonstrates that durable responses can occur upon retreatment with decitabine... - AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agentAmanda F Cashen
Washington University School of Medicine, Division of Oncology, 660 South Euclid Avenue, Campus Box 8007, St Louis, MO 63110, USA
Future Oncol 3:19-27. 2007..In Phase II trials, mobilization with the combination of AMD3100 and granulocyte colony-stimulating factor (G-CSF) results in the collection of more progenitor cells than G-CSF alone... - Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)Amanda F Cashen
Department of Medicine, Division of Bone Marrow Transplantation and Stem Cell Biology, Washington University School of Medicine, 660 S Euclid Ave, Box 8007, St Louis, MO 63110, USA
Cancer Chemother Pharmacol 61:759-66. 2008..In this study, pharmacokinetics (PK) of decitabine administered as a 3-h intravenous infusion of 15 mg/m2 every 8 h for 3 days (cycles repeated every 6 weeks) was evaluated in patients with MDS or AML... - Therapy of relapsed Hodgkin lymphomaAmanda F Cashen
Division of Oncology, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110, USA
Blood Rev 21:233-43. 2007..New salvage regimens that incorporate gemcitabine, vinorelbine, rituximab, and/or monoclonal antibodies against CD30 are being investigated... 
A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphomaAmanda Cashen
Washington University School of Medicine, St Louis, Missouri 63110, USA
Biol Blood Marrow Transplant 14:1253-61. 2008..The PK of plerixafor in this patient population was similar to that previously seen in healthy volunteers. The regimen was generally safe and well tolerated...- Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemiaAmanda F Cashen
Washington University School of Medicine, St Louis, MO, USA
J Clin Oncol 28:556-61. 2010..We investigated the efficacy and toxicity of the hypomethylating agent decitabine as initial therapy in older patients with AML... 
Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantationJacob P Smeltzer
Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
Biol Blood Marrow Transplant 17:1646-52. 2011..2 (confidence interval [CI] 1.1-9.0, P = .03). Pre-ASCT FDG-PET scans predict EFS in patients with relapsed cHL patients treated with modern salvage/ASCT therapy and warrant prospective evaluation...- Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantationIskra Pusic
Washington University School of Medicine, Siteman Cancer Center, St Louis, Missouri 63110, USA
Biol Blood Marrow Transplant 14:1045-56. 2008..Patients who fail initial mobilization are more likely to fail remobilization. These findings suggest that there is a need for more effective first-line mobilization agents... - Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cellsGeoffrey L Uy
Washington University School of Medicine, Division of Oncology, 660 S Euclid Avenue, Campus Box 8007, St Louis, Missouri 63110, USA
Expert Opin Biol Ther 8:1797-804. 2008.... - A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemiaGeoffrey L Uy
Division of Oncology, Washington University School of Medicine, 660 S Euclid Avenue, St Louis, MO 63110, USA
Blood 119:3917-24. 2012..We conclude that the addition of plerixafor to cytotoxic chemotherapy is feasible in AML, and results in encouraging rates of remission with correlative studies demonstrating in vivo evidence of disruption of the CXCR4/CXCL12 axis... - A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphomaTodd A Fehniger
Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
Blood 118:5119-25. 2011..This trial is registered at www.ClinicalTrials.gov as NCT00540007... - Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSFMike G Martin
Section of Leukemia and Bone Marrow Transplantation, Division of Oncology, Washington University School of Medicine, Saint Louis, Missouri, USA
Am J Hematol 84:733-7. 2009..The patients who received G-CSF concurrently with chemotherapy had improved outcomes. Am. J. Hematol., 2009. (c) 2009 Wiley-Liss, Inc... - A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemiaTodd A Fehniger
Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine, St Louis, MO, USA
Blood 117:1828-33. 2011..HD lenalidomide has evidence of clinical activity as initial therapy for older AML patients, and further study of lenalidomide in AML and MDS is warranted. This study is registered at www.clinicaltrials.gov as #NCT00546897... - A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromesMike G Martin
Washington University School of Medicine, Saint Louis, Missouri 63110, USA
Am J Hematol 84:560-4. 2009..This regimen appeared to offer a PR + CR rate and median DOR somewhat similar to what has been reported with the 7-day subcutaneous regimen; however, OS was shorter... - 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretationAmanda F Cashen
Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
J Nucl Med 52:386-92. 2011..18)F-FDG PET may also be predictive of outcome when performed during the treatment course of DLBCL, but robust prospective studies and standardization of (18)F-FDG PET interpretation in this setting are lacking... - Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cellsAmanda F Cashen
Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
Drugs Today (Barc) 45:497-505. 2009..This review will summarize clinical trials, current use for autologous stem cell mobilization and future directions for plerixafor... - Cytokines and stem cell mobilization for autologous and allogeneic transplantationAmanda F Cashen
Division of Oncology, 660 South Euclid Ave, Washington University, St. Louis, MO 63110, USA
Curr Hematol Rep 3:406-12. 2004..Here we review recent studies that advance our understanding of the biology of stem cell mobilization. We then discuss cytokines in current use and in development for mobilization of autologous and allogeneic peripheral blood stem cells...